Differential roles of p21Waf1 and p27Kip1 in modulating chemosensitivity and their possible application in drug discovery studies

Molecular Pharmacology

Volumn 60, Issue 5, 2001, Pages 900-906

  Schmidt, Mathias ^a,c   Lu, Yang ^a   Parant, John M ^a   Lozano, Guillermina ^a   Bacher, Gerald ^b,d   Beckers, Thomas ^b,c   Fan, Zhen ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b ASTA MEDICA AG   (Germany)

^c ALTANA PHARMA AG   (Germany)

^d Axxima Pharmaceuticals AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; D 24851; DOXORUBICIN; ECDYSONE; ETOPOSIDE; FLUOROURACIL; MELPHALAN; N (PYRIDIN 4 YL)[1 (4 CHLOROBENZYL)INDOL 3 YL]GLYOXYLAMIDE; PROTEIN P21; PROTEIN P27; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CELL CYCLE; CHEMOSENSITIVITY; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG RESEARCH; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MITOSIS INDEX; PRIORITY JOURNAL; WESTERN BLOTTING;

EID: 0034752731     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.60.5.900     Document Type: Article

References (31)

1. Paclitaxel in head and neck and other cancers: Future prospects
2. D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity
3. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA
4. Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines
5. 2 cell cycle arrest in p53-deficient cells
6. Kip1 for restriction point control of the fibroblast cell cycle
7. 1 arrest
8. Cip1/WAF1/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition
9. CDK inhibition and cancer therapy
10. 1 cyclin-dependent kinases
11. Cyclins and cell cycle checkpoints
12. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage
13. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage
14. waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases
15. Induction of WAF1/CIP1 by a p53-independent pathway
16. 2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication
17. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest
18. Kip1 by cDNA antisense suppresses quiescence (G0 state) in fibroblasts
19. Paclitaxel pharmacology and other tumor types
20. Overexpressed WAF1/Cip1 renders glioblastoma cells resistant to chemotherapy agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin
21. Protection against chemotherapy-induced cytotoxicity by cyclin-dependent kinase inhibitors (CKI) in CKI-responsive cells compared with CKI-unresponsive cells
22. kiP1
23. 1-phase progression
24. Kip1 on resistance of tumor cells to anticancer agents
25. Kip1
26. 1 cyclin-Cdk protein kinase activity, is related to p21
27. Inactivation of p53 and of pRb protects human colorectal carcinoma cells against hyperthermia-induced cytotoxicity and apoptosis
28. 1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody
29. Cip1/waf1 on growth and differentiation in human colon carcinoma cells